Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Chemomab Therapeutics (Nasdaq: CMMB) has announced its participation in the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. CEO Dr. Adi Mor and senior management will deliver a corporate presentation at 8:00 am ET, which will be webcast live and available on the company's website for 90 days.
Chemomab is advancing CM-101, a first-in-class monoclonal antibody targeting CCL24, for fibro-inflammatory diseases. The company recently reported positive results from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC). Two key milestones are expected in early 2025: establishing an FDA registrational pathway for CM-101's Phase 3 pivotal trial and reporting data from the SPRING trial open label extension.
The company plans to initiate the PSC Phase 3 trial by year-end. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. Additionally, their CM-101 program for systemic sclerosis is Phase 2-ready with an open U.S. IND.
Chemomab Therapeutics (Nasdaq: CMMB) ha annunciato la sua partecipazione alla virtuale Oppenheimer 35th Annual Healthcare Life Sciences Conference l'11 febbraio 2025. Il CEO Dr. Adi Mor e il management senior presenteranno una relazione aziendale alle 8:00 ET, che sarà trasmessa in diretta e disponibile sul sito web dell'azienda per 90 giorni.
Chemomab sta avanzando CM-101, un anticorpo monoclonale di prima classe che prende di mira CCL24, per le malattie fibro-infiammatorie. L'azienda ha recentemente riportato risultati positivi dal suo trial di Fase 2 SPRING nella colangite sclerosante primaria (PSC). Due traguardi chiave sono attesi all'inizio del 2025: l'istituzione di un percorso di registrazione FDA per il trial pivotale di Fase 3 di CM-101 e la comunicazione dei dati dall'estensione dell'etichetta aperta del trial SPRING.
L'azienda prevede di avviare il trial di Fase 3 per la PSC entro la fine dell'anno. CM-101 ha ricevuto le designazioni di Farmaco Orfano da FDA e EMA e la designazione Fast Track da parte della FDA per il trattamento della PSC. Inoltre, il loro programma CM-101 per la sclerosi sistemica è pronto per la Fase 2 con un IND aperto negli Stati Uniti.
Chemomab Therapeutics (Nasdaq: CMMB) ha anunciado su participación en la Oppenheimer 35th Annual Healthcare Life Sciences Conference virtual el 11 de febrero de 2025. El CEO Dr. Adi Mor y la alta dirección realizarán una presentación corporativa a las 8:00 am ET, que se transmitirá en vivo y estará disponible en el sitio web de la empresa durante 90 días.
Chemomab está avanzando CM-101, un anticuerpo monoclonal de primera clase que apunta a CCL24, para enfermedades fibro-inflamatorias. La compañía reportó recientemente resultados positivos de su ensayo de fase 2 SPRING en colangitis esclerosante primaria (PSC). Se esperan dos hitos clave a principios de 2025: establecer un camino de registro de FDA para el ensayo pivotal de fase 3 de CM-101 y reportar datos de la extensión de etiqueta abierta del ensayo SPRING.
La compañía planea iniciar el ensayo de fase 3 para PSC antes de fin de año. CM-101 ha recibido las designaciones de Medicamento Huérfano de la FDA y EMA y la designación de Vía Rápida de la FDA para el tratamiento de PSC. Además, su programa CM-101 para esclerosis sistémica está listo para fase 2 con un IND abierto en EE. UU.
Chemomab Therapeutics (Nasdaq: CMMB)는 2025년 2월 11일에 열리는 Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 가상 참여한다고 발표했습니다. CEO 아디 모르 박사와 고위 경영진은 동부 표준시 기준 8:00에 기업 발표를 진행하며, 이는 실시간으로 방송되고 회사 웹사이트에서 90일간 제공될 것입니다.
Chemomab는 섬유-염증 질환을 대상으로 하는 1등급 단클론 항체인 CM-101을 개발하고 있습니다. 최근 이 회사는 주기 알레르기성 담관염(PSC)에서의 2상 SPRING 시험에서 긍정적인 결과를 보고했습니다. 2025년 초에는 두 가지 주요 이정표가 예상됩니다: CM-101의 3상 피벗 시험을 위한 FDA 등록 경로 설정과 SPRING 시험의 공개 레이블 확장 데이터 보고입니다.
회사는 연말까지 PSC 3상 시험을 시작할 계획입니다. CM-101은 PSC 치료를 위해 FDA 및 EMA에서 오르판 약물 및 FDA의 패스트트랙 지정을 받았습니다. 또한, 전신 경화증을 위한 CM-101 프로그램은 미국에서 개방된 IND와 함께 2상 준비가 완료되었습니다.
Chemomab Therapeutics (Nasdaq: CMMB) a annoncé sa participation à la 35e Conférence Annuelle sur la Santé et les Sciences de la Vie d'Oppenheimer virtuelle le 11 février 2025. Le PDG Dr. Adi Mor et la direction senior feront une présentation d'entreprise à 8h00 ET, qui sera diffusée en direct et disponible sur le site web de l'entreprise pendant 90 jours.
Chemomab fait progresser CM-101, un anticorps monoclonal de première classe ciblant CCL24, pour les maladies fibro-inflammatoires. La société a récemment rapporté des résultats positifs de son essai de Phase 2 SPRING dans la cholangite sclérosante primitive (PSC). Deux jalons clés sont attendus début 2025 : établir une voie d'enregistrement FDA pour l'essai pivot de Phase 3 de CM-101 et communiquer les données de l'extension en ouvert de l'essai SPRING.
L'entreprise prévoit de lancer l'essai de Phase 3 pour la PSC d'ici la fin de l'année. CM-101 a reçu les désignations de Médicament Orphelin de la FDA et de l'EMA ainsi que la désignation Voie Rapide de la FDA pour le traitement de la PSC. De plus, leur programme CM-101 pour la sclérose systémique est prêt pour la Phase 2 avec un IND ouvert aux États-Unis.
Chemomab Therapeutics (Nasdaq: CMMB) hat seine Teilnahme an der virtuellen 35. jährlichen Healthcare Life Sciences Conference von Oppenheimer am 11. Februar 2025 angekündigt. CEO Dr. Adi Mor und das Senior Management werden um 8:00 Uhr ET eine Unternehmenspräsentation halten, die live übertragen und 90 Tage lang auf der Webseite des Unternehmens verfügbar sein wird.
Chemomab entwickelt CM-101, einen ersten monoklonalen Antikörper, der auf CCL24 abzielt, zur Behandlung von fibro-inflammatorischen Erkrankungen. Das Unternehmen hat kürzlich positive Ergebnisse aus der Phase-2-Studie SPRING bei der primären sklerosierenden Cholangitis (PSC) veröffentlicht. Zwei wichtige Meilensteine werden Anfang 2025 erwartet: die Etablierung eines FDA-Registrierungspfads für die Phase-3-Wendeprüfung von CM-101 sowie die Datenbekanntgabe der offenen Labelverlängerung der SPRING-Studie.
Das Unternehmen plant, die PSC-Phase-3-Studie bis Ende des Jahres zu starten. CM-101 hat von der FDA und der EMA den Status als Orphan Drug sowie die Fast-Track-Designierung der FDA zur Behandlung der PSC erhalten. Darüber hinaus ist ihr CM-101-Programm für systemische Sklerose bereit für Phasen 2 mit einer offenen IND in den USA.
- None.
- None.
TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The Oppenheimer Conference presentation will be webcast live and will be available on the investor relations section of the Chemomab website for 90 days.
| Oppenheimer 35th Annual Healthcare Life Sciences Conference | |
| Date: | February 11, 2025 |
| Time: | 8:00 am ET |
| Venue: | Virtual |
| Format: | Webcast presentation |
| Webcast Link: | https://wsw.com/webcast/oppenheimer39/cmmb/2752408 |
| Information: | opcoconferences@opco.com |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025 – achieving a clear FDA registrational pathway for the planned CM-101 Phase 3 pivotal trial and reporting data from the SPRING trial open label extension. Chemomab is targeting initiation of the PSC Phase 3 trial before the end of the year. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
When will Chemomab (CMMB) present at the Oppenheimer Healthcare Conference 2025?
What are the key milestones expected for Chemomab's CM-101 drug in early 2025?
What regulatory designations has CM-101 received for PSC treatment?
When does Chemomab (CMMB) plan to start the Phase 3 trial for CM-101 in PSC?
What diseases is Chemomab's CM-101 being developed to treat?
